Literature DB >> 7902344

Epidemiological and immunological study of HIV-seropositive Ethiopian immigrants in Israel. The Israel AIDS Study Group.

S Pollack1.   

Abstract

A cohort of 243 HIV-seropositive Ethiopian immigrants has been studied clinically and immunologically since their arrival in Israel in May 1991. The prevalence of HIV infection in this Ethiopian community is 1.74%, with a male to female ratio of 1.3:1. The median age is 30 years; women are somewhat younger (median 29) than men (median 33). The prevalence of HIV infection among Ethiopian immigrants is similar to the estimated rate found in the general population in Ethiopia (1.85%). Blood median counts of CD4 positive and CD8 positive T cells on first determination were 391 and 878 x 10(6)/l respectively. The number of HIV carriers with CD4 levels below 300 and 200 x 10(6)/l in a subcohort of 172 individuals was 52 (30.2%) and 26 (15.1%), respectively. The vast majority (> 90%) of the cohort are still clinically asymptomatic. This, and the fact that immigrants tested prior to 1991 were all HIV negative, attest to the recent introduction of HIV infection into this population. In spite of the recency of HIV infection, CD4 counts were relatively low in a high proportion of infected individuals.

Entities:  

Mesh:

Year:  1993        PMID: 7902344

Source DB:  PubMed          Journal:  Isr J Med Sci        ISSN: 0021-2180


  3 in total

Review 1.  Host background immunity and human immunodeficiency virus protective vaccines, a major consideration for vaccine efficacy in Africa and in developing countries.

Authors:  Gadi Borkow; Zvi Bentwich
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

2.  Cross-cultural medicine and diverse health beliefs. Ethiopians abroad.

Authors:  R Hodes
Journal:  West J Med       Date:  1997-01

Review 3.  Infectious diseases among Ethiopian immigrants in Israel: a descriptive literature review.

Authors:  Yulia Treister-Goltzman; Ali Alhoashle; Roni Peleg
Journal:  Pathog Glob Health       Date:  2021-02-24       Impact factor: 2.894

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.